Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$29.56M$29.56M−28.7% vs Q3 2023 Net Income-$29.92M-$29.92MN/M vs Q3 2023 EPS Diluted-$2.03-$2.03N/M vs Q3 2023 Gross Profit$1,440,000−94.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$5,016,000−22.7% Free Cash Flowderived$3,800,000−33.8% Margins · derivedGross margin4.9%−55.3 pt vs Q3 2023
Operating margin-94.8%−76.3 pt vs Q3 2023
Net margin-101.2%−85.4 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end